We are an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. We launched the iStent®, our first MIGS device, in the United States in July 2012 and we are leveraging our platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. We believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide.

View Stock Information

Financials & Filings

Access our filings with the Securities and Exchange Commission (SEC) via the link below. These filings are also available at www.sec.gov.

View Financials & Filings

Events & Presentations

Access information about recent and upcoming investor events via the link below.

View Events & Presentations

Contact Investor Relations

Glaukos Corporation
229 Avenida Fabricate
San Clemente, CA 92672

Telephone: 949-367-9600 ext 371
Fax: 949-367-9984
Email: investors@glaukos.com